Purpose. This study is aimed at investigating the association between the metabolic score for insulin resistance (METS-IR) index and nonalcoholic fatty liver disease (NAFLD) in the nonobese population and its predictive value. Methods. 10730 nonobese subjects were selected from longitudinal cohort research conducted from January 2010 to December 2014. Cox proportional hazards models were employed to assess the relationship between METS-IR and new-onset NAFLD. Generalized additive models were used to identify nonlinear relationships. In addition, we performed subgroup analyses and interaction tests. The time-dependent receiver operating curve (ROC) and area under the ROC (AUC) were utilized to measure the discriminatory ability of METS-IR for new-onset NAFLD. Beyond clinical risk factors, the incremental predictive value of METS-IR was appraised using integrated discrimination improvement (IDI), C-index, and net reclassification index (NRI). Results. Over a median period of 804.50 days of follow-up, 1859 (17.33%) participants had a new onset of NAFLD. After adjusting for confounders, the HR for new-onset NAFLD in the Q4 group was 6.40 compared with the Q1 group. When METS-IR was considered a continuous variable, the risk of NAFLD increased by 34% for every 1 SD increase in METS-IR. The smoothing curve shows the dose-response relationship between METS-IR and the presence of new-onset NAFLD. Using a two-piecewise linear regression model, we derived a METS-IR inflection point of 36. HRs were 1.31 on the left side of the inflection point and 1.04 on the right side of the inflection point (log-likelihood ratio test, P < 0.001 ). Subgroup analyses and interaction tests revealed an interaction between gender and SBP in the association between METS-IR and new-onset NAFLD. In the subgroup analysis of gender and SBP, we observed a higher risk of new-onset NAFLD in men and in those with abnormal SBP levels. We evaluated the ability of METS-IR to identify new-onset NAFLD at different time points. The AUCs at 1, 2, 3, and 4 years were 0.784, 0.756, 0.758, and 0.752, respectively, which represent good discrimination of new-onset NAFLD. The addition of METS-IR greatly improved the reclassification and differentiation of clinical risk factors, with an NRI of 0.276 and an IDI of 0.068. In addition, the addition of METS-IR increased the C-index from 0.719 to 0.771. Conclusion. In a nonobese Chinese population, elevated METS-IR was independently associated with an enhanced risk of NAFLD development and a dose-response relationship existed. In addition, METS-IR might be a reliable indicator for screening individuals at risk for early NAFLD, especially in nonobese populations.

No abstract

Objectives. Systemic vasculitis includes a group of disorders characterized by inflammation of the vessel wall, involving multiple systems, and can cause malignant hypertension. CD163 is a specific marker of anti-inflammatory macrophages. This study is aimed at evaluating the CD163 levels in relation to systemic vasculitis and renal involvements. Methods. Urinary CD163 levels were retrospectively measured by enzyme-linked immunosorbent assay (ELISA) in 51 patients with systemic vasculitis, 42 essential hypertensions, and 36 healthy volunteers. The associations between urinary CD163 levels and clinical indicators were analyzed. Results. Urinary CD163 levels were significantly higher in patients with systemic vasculitis [68.20 (38.25~158.78) (pg/ml)] compared to essential hypertension [43.86 (23.30-60.71) (pg/ml)] ( p = 0.003 ) and the healthy volunteers [30.76 (9.30-54.16) (pg/ml)] ( p < 0.001 ). Furthermore, systemic vasculitis patients with renal involvement had significantly higher urinary CD163 levels relative to patients without renal involvement [86.95 (47.61 and 192.38) pg/ml] vs. [41.99 (17.70 and 71.95) pg/ml, p = 0.005 ]. After control factors age, sex, and BMI, urinary CD163 levels in systemic vasculitis patients were positively correlated with serum creatinine, blood urea nitrogen, and β-2 microglobulin ( r = 0.45 , 0.48, and 0.46; p = 0.001 , 0.001, and 0.002, respectively). In addition, we found the level of urinary CD163 in granulomatous vasculitis (including TA, GPA, and EGPA) was significantly higher than that in necrotizing vasculitis (including PAN) [86.95 (41.99 and 184.82) pg/ml] vs. [45.73 (21.43 and 74.43) pg/ml, p = 0.016 ]. Conclusion. Urinary CD163 levels were significantly higher in patients with systemic vasculitis, especially in patients with renal involvement. Thus, urinary CD163 has the potential to be a biomarker for systemic vasculitis with renal involvement.

Background: Transcatheter adrenal ablation as an alternative treatment for primary aldosteronism(PA) patients is still controversial and the outcomes varies widely in existing studies. The aim of this meta-analysis is to evaluate the result of adrenal ablation and estimate effectiveness and safety of this therapy method. Methods: A comprehensive search was performed across Pubmed, Embase and Cochrane Library databases for studies published up to October 2022. The outcomes analyzed were the combined clinical success rate, biochemical success rate and complication rate, which was employed with a random-effects model. Results: Five studies comprising 234 PA patients were included in the study. The combined clinical success rate was 74% (95% CI: 69%-79%) and the bichemical success rate was 74%(95%CI: 53%-95%). Subgroup analysis showed that the combined clinical success rate from Unilateral PA (72%, 95%CI: 46%-98%) was similar to the rate from Unilateral+bilateral(73%, 95%CI :52.0%-94.0%) and the clinical success rate of PASO subgroup(78%, 95%CI: 66.0%-89.0%) was higher than the rate of other criteria(51%, 95%CI: 40.0%-63.0%). The combined complication rate of mild fever was 23% (95% CI: 12%- 33%), back pain was 84% (95% CI: 77%- 91%) and pleural effusion was 9% (95%CI: 0% -18%). All complications disappeared within one week after the procedure. There were no late complications or ablation-related deaths. Conclusions: The transcatheter adrenal ablation for PA patients is safe and has a relatively high clinical success rate. Currently, this approach is suitable for PA patients unwilling to accept surgery and long-term mineralocorticoid receptor antagonists(MRAs) treatment. Systematic Review Registration: INPLASY, identifier 2022110076

No abstract